Five Year Study to Track Use of DecisionDX-Melanoma Test in Patients With Cutaneous Melanoma and Associated Patient Outcomes

Stopped early

Conditions studied: Cutaneous Melanoma

In brief

The EXPAND Registry Study follows patients with cutaneous melanoma who have had the DecisionDx-Melanoma gene expression assay performed as part of their clinical care. Data will be collected through review of medical records from clinical visits with physician. The purpose is to document the clinical application of results obtained from the DecisionDx- Melanoma multi-gene assay and to track outcomes of patients for whom DecisionDx-Melanoma testing has been completed. Additionally the study will assess the health economic impact of DecisionDx-Melanoma testing as it relates to the Melanoma population.

Key facts

Study ID

NCT02355587

Run by

Castle Biosciences Incorporated

People needed

72

Starts

2014-03-01

Expected to finish

2021-07-31

Last updated by the study team

2021-10-08

Who can join

Age: 16 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients diagnosed with melanoma and determined, by their physician, to be appropriate for DecisionDx-Melanoma testing and who have successful results available to the investigator are eligible for registration
• Patients enrolled should be reasonably able to follow-up with the enrolling physician at regular intervals for assessment of outcome data.
• 16 Years and older

You may not qualify if…

• Less than 16 Years of age

Where it is running

• Sutter Health — Santa Rosa, California, United States
• Elizabeth Liotta Dermatology — Frederick, Maryland, United States
• University of Nevada — Las Vegas, Nevada, United States
• South Carolina Skin Care Center — Greenville, South Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.